IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Eyal Shamir - CEO Ronen Tsimerman - CFO & COO Todd Kehrli - EVC Group, IR Conference Call Participants Kemp Dolliver - Brookline Capital Markets Ben Haynor - Alliance Global Partners Chaitanya G. - H.C. Wainwright Operator Good morning, and thank you for standing by. [Operator instructions]. I would now like to turn the conference over to Todd Kehrli. Please go ahead. Todd Kehrli Thank you, Ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission ...

Exhibit 99.1 IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023 ● Rising Awareness and Utilization of ProSense System: System and disposables sales in the U.S. represented 20% of 2022 revenues, up from 11% in 2021, as increased utilization of systems generated a 28% year-over-year increase in U.S. sales. Worldwide, disposable sales accounted for 43% of 2022 revenue, up from 29% in 2021. ● Filed for FDA Mar ...

IceCure Medical Ltd (NASDAQ:ICCM) Q3 2022 Results Conference Call December 2, 2022 8:00 AM ET Company Participants Eyal Shamir - Chief Executive Officer Ronen Tsimerman - Chief Financial Officer Hania Bednarski - Oncoplastic Breast Surgeon and Cryoablation Specialist Conference Call Participants Ben Haynor - Alliance Global Partners Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Welcome to IceCureÂ's Conference Call on the Financial Results for the Nine Months Ended Septem ...

Exhibit 99.1 "We have edged closer to commercialization of ProSense for breast cancer in the U.S. with our recent FDA filing for marketing approval, and the assignment of a Medicare CPT III reimbursement code. IceCure has taken a leadership role in the industry based on our vast ICE 3 breast cancer cryoablation clinical data and by receiving the CMS's first payment assignment for cryoablation of breast cancer," stated IceCure's CEO Eyal Shamir. "While our quarterly revenues may continue to fluctuate in the ...

Exhibit 99.1 The accompanying notes are an integral part of the consolidated financial statements. 1 ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (U.S. dollars in thousands, except share data and per share data) ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (U.S. dollars in thousands, except share data and per share data) | | As of | As of | | --- | --- | --- | | | June 30, | December 31, | | | 2022 | 2021 | | ASSETS | | | | CUR ...

Financial Data and Key Metrics Changes - For the six months ended June 30, 2022, revenue decreased by 27% to $1.5 million, compared to $2.1 million in the first half of last year, primarily due to reduced revenue recognition from distribution agreements and decreased sales in Asia due to COVID-19 impacts [24][30] - Gross profit was approximately $800,000 with a gross margin of approximately 54%, down from approximately $1.2 million and 58% respectively in the same period of 2021 [26] - Net loss increased to approximately $9 million or $0.24 per share, compared to a net loss of approximately $3.8 million or $0.16 per share for the same period last year [30] Business Line Data and Key Metrics Changes - The company signed an exclusive distribution agreement in Mainland China for IceSense3, with a minimum purchase target of $3.5 million over the first three years [10][13] - ProSense systems were sold and installed in several clinics worldwide, including the U.S., Turkey, and Poland, with expectations for increased installations based on commercial interest [15][16] Market Data and Key Metrics Changes - The healthcare market in China is expected to reach $2.3 trillion by 2030, driven by government investments in healthcare infrastructure [12] - The company is actively expanding its regulatory landscape, with applications filed in Brazil and Canada for the ProSense system [17][18] Company Strategy and Development Direction - The company aims to expand its regulatory and commercial strategies, focusing on the adoption of its minimally-invasive cryoablation technology [5][21] - Management highlighted the importance of the distribution agreement with Medtronic as a strategic milestone for market penetration in China [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future revenue growth driven by increased installations and sales of ProSense systems [21] - The management team is focused on advancing regulatory approvals and expanding clinical applications, with expectations for revenue recognition from the new distribution agreement in the second half of 2022 [14][21] Other Important Information - The company participated in 10 conferences and events during the second quarter, showcasing its technology and gaining traction within the medical community [19][20] - The ICE3 clinical trial is expected to provide final results by the end of 2023 or early 2024, which could further validate the technology [34] Q&A Session Summary Question: Can you share updated patient follow-up data from the trial? - By June 2022, 82 patients had completed the trial with follow-ups of up to five years, with a local recurrence rate of 2.06% [75][78] Question: Is this a reasonable run rate to think about for the full year? - The company believes that spending levels will remain consistent with the first half of the year, indicating a flexible budget to accommodate necessary changes [81] Question: What are the differences in breast cancer patients seen by the company versus breast surgeons? - The patients seen are largely the same, with collaboration between the company and breast surgeons in the ICE3 trial [82] Question: What is the regulatory strategy for FDA submissions? - The first indication planned for submission is for low-risk early-stage T1 invasive breast cancer, based on interim results [85]

IceCure Medical Ltd. (NASDAQ:ICCM) Q1 2022 Earnings Conference Call May 18, 2022 8:30 AM ET Company Participants Eyal Shamir - Chief Executive Officer Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Richard Fine - Investigator of ICE3 Clinical Trial Conference Call Participants Ben Haynor - Alliance Global Partners Kemp Dolliver - Brookline Capital Markets Operator Welcome to IceCureÂ's First Quarter 2022 Results Conference Call. Management will provide an overview of IceCureÂ's financ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission ...